A carregar...
Publicação
Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 823.84 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.
Descrição
Funding Information: The study was funded by ViiV Healthcare. Medical writing and editorial assistance with the preparation of this manuscript was provided by Karolina Badora, PhD, of Maple Health Group, and funded by ViiV Healthcare. The study sponsor had a role in the study design, data collection and analysis, and preparation of the manuscript. The decision to publish was made by the authors. The study was funded by ViiV Healthcare. Medical writing and editorial assistance with the preparation of this manuscript was provided by Karolina Badora, PhD, of Maple Health Group, and funded by ViiV Healthcare. The study sponsor had a role in the study design, data collection and analysis, and preparation of the manuscript. The decision to publish was made by the authors. I have read the journal\u2019s policy and the authors of this manuscript have the following competing interests: JF and SS are employees of ViiV Healthcare and own stock in GSK; JF owns stock in Gilead Sciences. SJA is an employee of and owns stock in GSK. FA is an employee of Incremental Action Consulting, Lda, and owns stock in Gilead Sciences. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare. Medical writing and editorial assistance with the preparation of this manuscript was provided by Karolina Badora, PhD, of Maple Health Group. Publisher Copyright: © 2025 Fraysse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Palavras-chave
General SDG 3 - Good Health and Well-being